Antidiabetic Effect of Star Anise (Illicium verum) in Streptozotocin-induced Diabetic Rats.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2023-01-01 DOI:10.2174/1871529X23666230823112113

Smail Amtaghri, Adil Qabouche, Miloudia Slaoui, Mohamed Eddouks

{"title":"Antidiabetic Effect of Star Anise (Illicium verum) in Streptozotocin-induced Diabetic Rats.","authors":"Smail Amtaghri, Adil Qabouche, Miloudia Slaoui, Mohamed Eddouks","doi":"10.2174/1871529X23666230823112113","DOIUrl":null,"url":null,"abstract":"Aim: The current study aimed to evaluate the antidiabetic potential of Illicium verum fruits.Background: Illicium verum fruits are frequently used by the Moroccan population in the treatment of diabetes.Methods: The antihyperglycemic effect of the aqueous extract of Illicium verum fruits (AEIVF) in rats was assessed. The effects of AEIVF (20 mg/kg) on glycemia and lipid profile as well as its phytochemical and antioxidant properties were evaluated.Results: In normal and diabetic rats, AEIVF reduced blood glucose levels 6 hours after administration. Furthermore, after 7 days of treatment, glycemia was lowered in diabetic rats, and this extract exhibited an antioxidant activity.Conclusion: The study shows that Illicium verum possesses a potent antidiabetic activity. In addition, the toxicity of AEIVF was evaluated and the LD50 value was found to be greater than the 2 g/kg dose.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":" ","pages":"92-98"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X23666230823112113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The current study aimed to evaluate the antidiabetic potential of Illicium verum fruits.

Background: Illicium verum fruits are frequently used by the Moroccan population in the treatment of diabetes.

Methods: The antihyperglycemic effect of the aqueous extract of Illicium verum fruits (AEIVF) in rats was assessed. The effects of AEIVF (20 mg/kg) on glycemia and lipid profile as well as its phytochemical and antioxidant properties were evaluated.

Results: In normal and diabetic rats, AEIVF reduced blood glucose levels 6 hours after administration. Furthermore, after 7 days of treatment, glycemia was lowered in diabetic rats, and this extract exhibited an antioxidant activity.

Conclusion: The study shows that Illicium verum possesses a potent antidiabetic activity. In addition, the toxicity of AEIVF was evaluated and the LD₅₀ value was found to be greater than the 2 g/kg dose.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

八角茴香对链脲佐菌素诱导的糖尿病大鼠的抗糖尿病作用

目的：本研究旨在评估茵陈果实的抗糖尿病潜力：背景：摩洛哥人常用鸢尾果治疗糖尿病：方法：本研究评估了桔梗水提取物（AEIVF）对大鼠的降血糖作用。评估了 AEIVF（20 毫克/千克）对血糖和血脂的影响及其植物化学和抗氧化特性：结果：对于正常大鼠和糖尿病大鼠，AEIVF 在给药 6 小时后可降低血糖水平。此外，治疗 7 天后，糖尿病大鼠的血糖值降低了，而且这种提取物还具有抗氧化活性：研究表明，Illicium verum 具有很强的抗糖尿病活性。此外，还对 AEIVF 的毒性进行了评估，发现其半数致死剂量大于 2 克/千克的剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.